Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
States sue Abbott for 'blocking' generics
And the battle over generics rages on. Eighteen states have filed an antitrust suit against Abbott Laboratories, saying the drugmaker blocked generic competition for its blockbuster cholesterol med TriCor. According to the suit, which also names the French pharma Fournier, the companies continuously tweaked the TriCor formula to keep generic versions off the market. It also claims that they deceived the U.S. Patent Office with misleading data.
Abbott says it hasn't kept TriCor copycats off the market; in fact, there are eight competing products, according to a company spokeswoman. A Fournier rep says it didn't do anything wrong and intends to "vigorously defend itself" against the charges.
- see the release from Florida AG Bill McCollum
- read the complaint from the Florida AG's website
- see the International Herald Tribune story
- check out more details in the Chicago Tribune
Related Articles:
FTC sues Cephalon for blocking generics. Report
US Senate to take on authorized generics. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


